SCIBASE AB
About SCIBASE AB
SciBase AB is a global medical technology company specializing in early detection and prevention in dermatology. The company develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that integrates augmented intelligence (AI) with advanced Electrical Impedance Spectroscopy (EIS) technology. This platform is designed to elevate diagnostic accuracy, enable disease monitoring, and facilitate early intervention for various skin disorders, including melanoma, non-melanoma skin cancer, and atopic dermatitis.
Nevisense provides clinicians with objective, actionable data at the point of care, a capability that has been recognized by its inclusion in the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for melanoma, supporting its role as a diagnostic support technology. Furthermore, recent FDA approval has expanded the labeling for Nevisense, allowing other qualified healthcare professionals, such as physician assistants and medical assistants, to perform the procedure under the initiation of a dermatologist. This enhancement aims to streamline clinic workflows and improve patient access to this innovative diagnostic tool.
Built on over two decades of research at the Karolinska Institute in Stockholm, Sweden, SciBase is committed to minimizing patient suffering and improving outcomes by enabling timely detection and intervention, ultimately contributing to reduced healthcare costs.
Focus Areas
Business Intelligence
| Key Investors | Castle Biosciences, Van Herk Investments B.V., ÖstVäst Capital Management |
| Partnerships | Castle Biosciences, Skin Cancer and Reconstructive Surgery Center in California, Advanced Dermatology and Cosmetic Surgery group, Unified Health |
| Technology | Nevisense, AI (artificial intelligence)/augmented intelligence, advanced EIS (Electrical Impedance Spectroscopy) technology, point-of-care platform |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, SciBase's Nevisense platform offers a significant advantage by providing objective, non-invasive, and point-of-care data to improve diagnostic accuracy for melanoma and other skin disorders. This can lead to earlier detection of melanoma, which is almost 100% curable in its early stages, thereby improving patient outcomes and potentially saving lives. The technology aids in making more informed biopsy management decisions, helping to reduce unnecessary excisions of benign lesions. The recent FDA approval for extended labeling allows physician assistants and medical assistants to perform the Nevisense procedure (with dermatologist initiation), streamlining clinic workflows. Furthermore, its utility extends to assessing skin barrier function, offering insights for conditions like atopic dermatitis and supporting clinical research.
The Nevisense platform is designed for seamless integration into existing dermatology clinic workflows, particularly during routine total body skin cancer exams. The web-based Nevisense Dashboard allows for visualization, analysis, and export of measurement data, facilitating integration with other data analysis tools like Excel for further research or record-keeping. The expanded FDA labeling also supports easier integration by allowing a broader range of healthcare professionals to conduct the measurements.
What the Web Says
SciBase AB is a medical technology company specializing in the early detection and prevention of skin cancer through its Nevisense platform, which utilizes AI and Electrical Impedance Spectroscopy (EIS). The device, Nevisense, is FDA-approved for melanoma detection and is expanding its indications to include non-melanoma skin cancers. Reviews highlight the product's diagnostic accuracy and ease of integration into clinical workflows, while employer reviews are not readily available from the requested sources.
Overall: PositiveStrengths
- Clear diagnostic accuracy improvement over standard of care for melanoma detection.
- Fast results and easy to integrate into existing clinical workflows.
- Nevisense is the only FDA-approved AI-driven technology in dermatology for early detection of melanoma.
- Proprietary disposable electrodes allow optimal contact with skin and comprehensive measurement.
- Potential for expanded use to include non-melanoma skin cancers, broadening its market.
- Consumable electrodes provide a stable recurring revenue stream.
Limitations
- Company is in earlier stages of commercial journey with negative cash flow.
- Continuous investment in research and regulatory approvals for new applications.
- Uncertainty regarding the timing and costs of ramping up US sales.
- Limited information available on employer reviews from specified platforms.
Based on reviews from: GlobalData, Inderes, Simply Wall St, SciBase
Last updated: 2026-07-21
Videos
News, demos, and interviews about SCIBASE AB.
Videos load interactively. If none appear, search YouTube for SCIBASE AB →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]